Search

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, thus a novel chemotherapeutic agent for colon cancer therapy is needed. In this study, analogues of echinomycin, a cyclic peptide natural product with potent toxicity to several human cancer cell lines, were synthesized, and their biological activities against human colon cancer cells were investigated. Analogue 3 as well as 1 inhibit HIF-1α-mediated transcription. Notably, transcriptome analysis indicated that the cell cycle and its regulation were involved in the effects on cells treated with 3. Analogue 3 exhibited superior in vivo efficacy to echinomycin without significant toxicity in mouse xenograft model. The low dose of 3 needed to be efficacious in vivo is also noteworthy and our data suggest that 3 is an attractive and potentially novel agent for the treatment of colon cancer. [ABSTRACT FROM AUTHOR]

Iridoids are a large family of monoterpenoids found in traditional medicinal plants and show significant effects for the human species. In addition to their wide range of biological activities, such as neuroprotective and antitumor activities, the cis‐fused bicyclic ring systems of iridoids are still attractive as synthetic targets to apply novel synthetic methodologies. Accordingly, recent progress regarding the biosynthesis and chemical synthesis of iridoids is covered in this minireview. Identification of new enzymes for the iridoid biosynthesis in Catharanthus roseus and ingenious synthetic strategies for the construction of the iridoid skeleton are described. [ABSTRACT FROM AUTHOR]

Tunicamycins, which are nucleoside natural products, inhibit both bacterial phospho-N-acetylmuraminic acid (MurNAc)-pentapeptide translocase (MraY) and human UDP-N-acetylglucosamine (GlcNAc): polyprenol phosphate translocase (GPT). The improved synthesis and detailed biological evaluation of an MraY-selective inhibitor, 2, where the GlcNAc moiety was modified to a MurNAc amide, has been described. [ABSTRACT FROM AUTHOR]

[Display omitted] • Solid-phase synthesis of fluorescent probe of Park's nucleotide, lipid I and lipid II. • Introduction of fluorescent groups at the late stage of synthesis and sigle HPLC purification. • Potential to modular synthesis of functional analogues of Park's nucleotide, lipid I and lipid II. Solid-phase modular synthesis of fluorescent analogues of Park's nucleotide, lipid I and II, is described. The Fmoc protected lysine side chain of resin-bound intermediates were selectively modified by various fluorescent groups. This is the first example of solid-phase synthesis of these compounds. This synthetic strategy allows the preparation of various fluorescent probes for investigating the mechanisms of bacterial cell-wall biosynthesis. [ABSTRACT FROM AUTHOR]